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ABSTRACT
Objectives: We hoped to reveal the frequency of Aberrant Right Subclavian Artery (ARSA) and to find the relationship of 
isolated/non-isolated ARSA with chromosomal defects and other fetal congenital heart diseases (FCHD) in a heterogene-
ous population.
Material and methods: This was a retrospective cohort study conducted between December 2015 to September 2018. Wom-
en admitted for routine ultrasound examination or referred to our hospital for a suspected fetal anomaly were underwent 
detailed fetal anomaly ultrasonography scan and tested for the presence of ARSA.
Results: ARSA was detected in 27 patients and an isolated finding in 13 (48%) cases. Among 13 cases with isolated ARSA, 
trisomy 21 was diagnosed in 1 case. In the non-isolated group (n: 14, 52%), five cases presented with trisomy 21. There 
was no significant difference of trisomy 21 frequency between isolated and non-isolated groups (7.6% vs 35.7%, p = 0.08).  
In 3 patients, FCHD was diagnosed and 2 of them had trisomy 21. 
Conclusions: Our study shows that ARSA can be the only marker in trisomy 21. The examination of the subclavian artery 
must be a part of the fetal anomaly ultrasonography. Detecting an ARSA should increase the attentiveness of the sonog-
rapher to investigate for the other markers of trisomy 21. In the existence of other findings, invasive diagnostic procedures 
should be offered to the patients, whereas in cases that arsa is the only finding, other risk factors should be investigated 
to offer karyotyping or cell-free DNA analysis.
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INTRODUCTION
Aberrant right subclavian artery(ARSA) is the common 
seen abnormality or a variant of the aortic arch occurring in 
0.5% to 1.4% of the normal adult population [1]. ARSA is fea-
tured by different origination of the right subclavian artery 
from descending aorta directly instead of the brachiocephal-
ic trunk. Normally, the left aortic arch gives three branches, 
whereas with ARSA four vessels arise from the aortic arch; the 
right common carotid artery, the left common carotid artery, 
the left subclavian artery, and the ARSA, respectively [2, 3]. 
ARSA comes up from the distal portion of the aortic arch, and 
its route continues backwards the esophagus and the trachea 
and goes to the right shoulder (Fig. 1A and 1B). 
Most of the adult patients with ARSA have no symptoms, 
and it is usually a benign pathology. However, in some cases, 
it can cause dysphagia and partial airway obstruction due 
to the compression esophagus and trachea [4].
Figure 1A. Three-vessel trachea view showing aberrant right 
subclavian artery arising from the aorta and continuing behind the 
trachea
461
Mete Sucu et al., Outcome of fetuses with aberrant right subclavian artery
www. journals.viamedica.pl/ginekologia_polska
It was reported that ARSA may be a marker for trisomy 
21 such as absent nasal bone or thickened nuchal translu-
cency [5–7]. Furthermore, the association between ARSA 
and 22q11 microdeletion syndrome has also been reported 
[8]. However, it is important to keep in mind that ARSA 
can also be an isolated finding without any association with 
cardiac or extra-cardiac malformations.
In our study we aimed to determine the frequency of iso-
lated/non-isolated ARSA among a heterogenic population 
and to study its relation with chromosomal abnormalities, 
as well as different congenital anomalies including fetal 
congenital heart diseases (FCHD).
MATERIAl AND METhODS
This was a retrospective cohort study conducted in 
Cukurova University Faculty of Medicine between Decem-
ber 2015 and September 2018. The study included women 
attended our Fetal Medicine Clinic for routine second-tri-
mester fetal anomaly scanning or sent to our hospital dur-
ing the second/third trimester of pregnancy for a possible 
fetal anomaly or positive aneuploidy screening. All patients 
underwent a detailed fetal anomaly scan and were checked 
for the presence of ARSA. The findings of anomaly scan; 
presence of soft markers, cardiac and extracardiac con-
genital malformations, were noted. This was a heterogenous 
population including both low and high-risk patients. All 
patients were evaluated by four experienced observers 
using VolusonE6(GE Medical Systems, Zipf, Austria) with 
a transabdominal 4–8-MHz probe. The study was approved 
by the local ethics committee of Cukurova University Faculty 
of Medicine(approval number: 02.02.2018 74-2). All patients 
gave written informed consent for their data to be used.
Soft USG markers were as increased nuchal fold, hyper-
echogenic bowel, echogenic intracardiac focus, hypoplas-
tic/absent nasal bone, renal pyelectasis, shortened long 
bones(femur-humerus) and choroid plexus cyst.
Ultrasound technique for the diagnosis of ARSA
The three-vessel-trachea view is optimal for the diagno-
sis of ARSA. ARSA is demonstrated from the intersection of 
the aortic arch and ductus arteriosus with a course backward 
the trachea toward the right shoulder and arm. To demon-
strate its anomalous origin on the aortic arch and its retro-
tracheal course toward the right shoulder, colour-Doppler 
must be applicated in the three vessels and trachea view [2]. 
Pulsed-wave Doppler can be used to discriminate ARSA 
with the azygos vein, which courses to the right of the 
trachea. When ARSA was detected, it was also confirmed in 
the longitudinal aortic arc view [3]. These complementary 
approaches help to confirm the diagnosis of ARSA.
Fetal karyotyping with amniocentesis (cytogenetic analy-
ses and 22q11 microdeletion) was discussed with the parents 
when ARSA was diagnosed. All maternal-perinatal data were 
noted during ultrasound examination and after birth. In all 
cases where the karyotype was not performed prenatally, if 
the newborn had doubtful characteristics of a chromosomal 
anomaly, a peripheral blood karyotype test was performed. 
The karyotype was noted normal if the newborn had nor-
mal findings of physical examination. All the patients having 
a major fetal cardiac abnormality underwent both fetal and 
postnatal echocardiography by a pediatric cardiologist expe-
rienced with diagnosing fetal congenital heart anomalies. The 
diagnosis of isolated ARSA was done in accordance with the 
nonexistence of other ultrasound signs suggesting chromo-
somal abnormalities and/or fetal structural malformations 
after complete prenatal and postnatal evaluation. All cases 
of ARSA were confirmed by postnatal echocardiography.
All information of patients(including gestational age at 
diagnosis, delivery week, karyotype, 22q11 microdeletion, 
extra-cardiac malformations, additional cardiac findings, 
and postnatal outcome) were recorded and analyzed.
Descriptive statistics were done using Microsoft Excel. 
The Chi-square test was used for the comparison. A p-val-
ue < 0.05 was considered to indicate statistical significance.
RESUlTS
A total of 5283 fetuses were examined during the second 
or third trimester of pregnancies for a suspected fetal anom-
aly or routine ultrasound examination. The median gesta-
tional age was 23 weeks at diagnosis. The median age of 
the patients with ARSA was 30 years. ARSA was detected in 
27 cases (0.51%). ARSA was an isolated finding in 13 (48%) 
cases whereas in 14 cases (52%) ARSA was a non-isolated 
finding. In three cases (11.1%), ARSA was accompanied by 
other cardiac defects, whereas in six cases (22.2%) soft sono-
graphic markers were observed. Extracardiac malformations 
were present in four fetuses (14.8%). In one case (3.7%), only 
fetal growth restriction (FGR) accompanied ARSA. Clinical, 
demographic and USG findings are shownin Table 1.
Figure 1B. The vessel heads towards the right upper arm
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Prenatal karyotype analyses were performed in seven 
patients with isolated ARSA (53.8%) and revealed trisomy 
21 in 1 case. Postnatal evaluation of other patients with 
isolated ARSA was normal for trisomy 21.
In the non-isolated group, eight patients (57.1%) ac-
cepted prenatal karyotyping, and trisomy21 was diagnosed 
in four cases. In the postnatal evaluation of other six fetuses 
of the non-isolated group, the karyotype analysis result of 
five fetuses were noted normal because of the nonexistence 
of postnatal clinical findings suggesting choromosomal 
anomaly whereas 1 patient had clinical features of trisomy 
21 and karyotype analysis revealed trisomy 21.

















1 25 20 42 none none normal negative Healthy, 15 months old 
2 39 22 39 none none normal negative Healthy, 16 months old
3 26 20 39 none none NP NP Normal karyotype has dysphagia, 18 months old
4 29 23 39 none none NP NP Healthy, normal karyotype, 13 months old
5 24 21 37 none none Tri21 negative Tri21, 7 months old
6 34 25 32 none none NP NP Healthy, normal karyotype, 12 months old
7 32 20 37 none none normal negative Healthy, 13 months old
8 32 24 38 none none normal negative Healthy, 11 months old
9 38 20 37 none none normal negative Healthy, 15 months old
10 27 25 25 AVSD, PLSVC, DORV, PS SUA Tri21 negative Intrauterine exitus
11 21 23 41 none mild VM NP NP Healthy, normal karyotype, 7 months old
12 27 22 40 none none NP NP Healthy 6 months old
13 43 20 36 AVSD, BA mild VM, CLP, SUA NP NP Tri21, 5 months old
14 24 24 41 none VM, CLP, HB normal NP Postnatal exitus on the 1st day
15 34 25 34 none MCM, DA, NBH Tri21 NP Intrauterine exitus
16 34 21 33 none CPC, NBH Tri21 NP Tri21,16 months old
17 28 27 37 none FGR, HB NP NP Healthy, normal karyotype, 9 months old
18 39 23 33 none NBH, DB, SG, SF Tri21 NP Tri 21, 9 months old
19 26 23 40 none HB, NBH normal NP Unknown
20 35 23 39 none RP, INF,NBH normal NP 6 months old, operated for UPJO
21 21 26 41 none RP NP NP Healthy, normal karyotype, 30 months old
22 30 22 40 none none NP NP Healthy, normal karyotype, 28 months old
23 37 19 38 none INF normal NP Unknown
24 20 24 39 none none normal NP Healthy, 32 months old
25 31 25 40 none none NP NP Healthy, normal karyotype, 24 months old
26 33 27 39 none SUA normal NP Healthy, 36 months old
27 28 21 33 VSD none normal negative Healthy, 33 months old
NP — not performed; AVSD — atrioventricular septal defect; PLSVC — persistent left superior vena cava; DORV — double outlet right ventricle; PS — pulmonary 
stenosis; SUA — single umbilical artery; VM — ventriculomegaly; BA — bradiarithymi; CLP — cleft lip palate; MCM — mega cysterna magna; DA — duodenal atresia; 
NBH — nasal bone hypoplasia; CPC — choroid plexus cyst; FGR — fetal growth restriction; INF — increased nuchal fold; DB — dilatated bowel; SF — short femur; SG 
— sandal gap; HB — hyperechogenic bowel; RP — renal pelviectasia, VSD — ventricular septal defect; UPJO — ureteropelvic junction obstruction
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The frequency of trisomy 21 was 7.6% (1/13) in the iso-
lated group, and 35.7% (5/14) in the non-isolated group, 
and the difference was not statistically significant (p = 0.08). 
In total, six cases with the diagnosis of ARSA were found to 
have trisomy 21 (22%).
In the total study group, 31 fetuses had trisomy21 with 
the rate of 0.58% (31/5283). Among 31 fetuses with trisomy 
21, 6 fetuses had ARSA with the rate of 19.3% (6/31). In one 
of them ARSA was an isolated finding. ARSA rate was 0.39% 
(21/5252) in patients without trisomy 21. Trisomy 21 rate of 
patients with ARSA was 0.222 (6/27) whereas patients with-
out ARSA had a trisomy 21 rate as 0.004% (25/5256) and there 
was a 47 fold increase of trisomy 21 in patients with ARSA. 
DISCUSSION
The prevalence of ARSA was 0.51% in our study popu-
lation, which consists of both low and high-risk patients in 
a tertiary unit in Turkey. ARSA was an isolated finding in 13 of 
27 (48%) fetuses. Six fetuses had soft sonographic markers, 
three fetuses had other cardiac malformations, and four 
fetuses had extra-cardiac malformations.
There is an ongoing debate about whether invasive 
diagnostic procedures are indicated when ARSA is noted 
as an isolated finding. The relationship between ARSA and 
trisomy 21 was first described by Chaoui et al. [2]. These 
authors identified ARSA in 35.7% of fetuses with trisomy 
21 during the second and third trimester (5 of 14). We identi-
fied ARSA in 19.3% of fetuses with trisomy 21. Since then, 
ARSA was reported as one of the most powerful independ-
ent markers of trisomy 21 [7, 9, 10]. Agathokleous et al. [9] 
reported that trisomy 21 risk was increased about 3- to 4- 
fold in patients with ARSA but they emphasized that most 
of the studies in their meta-analysis were done in high-risk 
pregnancy groups. In our population trisomy 21 rate was 
47 fold increased in patients with ARSA. 
De Leon-Luis et al. [11] studied a large unselected popu-
lation and found 60 ARSA cases among 8781 fetuses, with 
a prevalence of 0.7%, which was higher than our study. 
Trisomy21 was diagnosed in seven(12%) of the 60 cases, 
all were in the non-isolated group(21 fetuses) and associ-
ated with the strong markers of trisomy21, such as absent 
or hypoplastic nasal bone, nuchal fold thickness, cystic 
hygroma, and ventriculomegaly, which also indicate per-
forming karyotype analysis. Trisomy21 rate of their patients 
with non-isolated ARSA was 33.3% and similar to our study 
with rate of 35.4%. Whereas in our study isolated ARSA 
group had a 7.6% trisomy21 rate, in their study no cases of 
trisomy21 were detected in fetuses with isolated ARSA. We 
evaluated the role of ARSA without USG markers associated 
with Trisomy21 and our data suggests that additional mark-
ers should be searched in these patients and family should 
be informed about trisomy21 risk. Even in the patients with 
isoleted ARSA increased trisomy21 risk must be taken into 
account.
Paladini et al. [7] studied a large trisomy21 group and 
found the incidence of 25% for ARSA. Borenstein et al. [12] 
and Paladini et al. [7] found that ARSA increased the risk of 
trisomy21 by about 16- to 20-fold.
Paladini et al. [7] diagnosed ARSA in 27 fetuses among 
the 106 fetuses with trisomy21; ARSA was the only finding 
in eight (30%) of these fetuses. Similarly we diagnosed ARSA 
in 6 fetuses among the 31 fetuses with trisomy21 and ARSA 
was the only finding in one of these cases. Based on these 
findings, they recommended that prenatal karyotyping 
analysis could be performed even in the cases of isolated 
ARSA [7]. Similarly, in the study of Gul et al. [13], the authors 
found Trisomy21 in one case of nine cases with isolated 
ARSA. In our study, one case (7.6%) presented with Down 
syndrome among the 13 cases with isolated ARSA.
While recommending amniocentesis for isolated ARSA 
cases, other risk factors should also be considered. Similarly, 
Esmer et al. [14] diagnosed trisomy21 with isolated ARSA in 
six fetuses; however, four cases had a positive first/second 
trimester screening test for trisomy21, and the remaining 
two of them had advanced maternal age. In three previous 
series, no case of trisomy21 with isolated ARSA was exist-
ed[6,15,16]. Yazicioglu et al. [6] concluded that the presence 
of ARSA without other sonographic findings is not a strong 
marker to recommend karyotyping and cell-free fetal DNA 
can be an alternative approach for these patients. In our 
study 7.6% of patients with isolated ARSA had trisomy21. Ac-
cording to these findings we suggest to explore additional 
risk factors to offer karyotyping or cell-free fetal DNA. 
Our findings show that nasal bone hypoplasia and single 
umbilical artery were the most frequent additional findings 
to ARSA, with rates of 18.5% and 11.1%, respectively. There-
fore, we agree with the idea of recommending karyotype 
analyses to the ARSA cases with additional findings. On the 
other hand, for the cases of isolated ARSA, screening test 
results should also be taken into account.
The close relationship between conotruncal anomalies 
and 22q11.2 microdeletion has been shown, especially if 
aortic arch anomalies (i.e., interrupted aortic arch, tetralogy 
of Fallot,ARSA, etc.) are existing additionally [8]. In our study, 
we also investigated the existence of 22q11.2 microdele-
tion besides the conventional cytogenetic analyses. Eight 
patients accepted microdeletion analyses, but no cases were 
detected to have 22q11.2 microdeletion. In the study of 
Rembouskos et al. [8], 22q11.2 microdeletion was catched 
in a case of ARSA with increased nuchal translucency. The 
authors suggested that FISH analyses for this microdeletion 
can be added to the cytogenetic analyses, even if there are 
no other cardiac defects that accompany ARSA. We believe 
that more prospective studies are needed to predicate the 
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relation between 22q11.2 microdeletion and ARSA without 
cardiac defects before it becomes an additional routine test.
One of the limitations of our study was the retrospec-
tive design of the study and low number of patients used 
to determine the prevalence of associated structural and 
chromosomal anomalies, microdeletion 22q11.2. In future 
work, more patients with isolated ARSA would be needed 
to determine the value of routine cytogenetic analyses for 
these patients.
CONClUSIONS
In conclusion, the visualization of the right subclavian ar-
tery is likely a valuable marker especially in patients with 
additional USG findings for trisomy 21 and should be a part 
of extended basic cardiac screening. The detection of ARSA 
should alert the examiner to seek additional sonographic 
markers. In existence of other signs suggesting trisomy21, 
we must offer invasive diagnostic procedures to the pa-
tients. Whereas in isolated cases, risk factors should be in-
corporated into the discussion about karyotype analyses or 
cell-free fetal DNA should be considered as a choice.
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